Published in J Immunol on November 01, 2005
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol (2006) 3.15
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res (2007) 2.20
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res (2009) 1.59
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res (2010) 1.44
Adoptive cell transfer therapy. Semin Oncol (2007) 1.44
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest (2015) 1.41
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 1.36
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood (2007) 1.32
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res (2007) 1.25
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother (2008) 1.21
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol (2009) 1.20
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther (2009) 1.17
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther (2008) 1.17
Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum Gene Ther (2009) 1.00
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther (2015) 0.97
A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A (2007) 0.96
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res (2015) 0.94
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother (2010) 0.92
High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother (2009) 0.91
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J Immunother (2008) 0.90
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
Genetically engineered T cells for the treatment of cancer. J Intern Med (2013) 0.83
A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther (2014) 0.83
Genetic engineering with T cell receptors. Adv Drug Deliv Rev (2011) 0.82
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
New approaches for the immunotherapy of acute myeloid leukemia. Discov Med (2015) 0.75
The mutational status of p53 can influence its recognition by human T-cells. Oncoimmunology (2017) 0.75
Advances and prospects in adoptive cell transfer therapy for ovarian cancer. Immunotherapy (2015) 0.75
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. J Cancer (2017) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
The p53 tumour suppressor gene. Nature (1991) 14.49
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 8.59
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Versatile retroviral vectors for potential use in gene therapy. Gene Ther (1994) 5.33
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics (1985) 5.30
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49
T-cell-receptor gene therapy. Nat Rev Immunol (2002) 3.31
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol (2005) 3.15
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol (1985) 3.13
Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 3.10
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med (1996) 2.73
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Immunotherapy through TCR gene transfer. Nat Immunol (2001) 2.41
CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A (1995) 2.09
Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol (2005) 1.93
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79
Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med (1997) 1.73
Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res (1992) 1.66
Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res (1996) 1.65
p53: 25 years after its discovery. Trends Pharmacol Sci (2004) 1.49
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
The physiological role of cytotoxic CD4(+) T-cells: the holy grail? Clin Exp Immunol (2004) 1.44
Tissue culture studies on pleural effusions from breast carcinoma patients. Cancer Res (1974) 1.42
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther (2004) 1.41
Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest (2002) 1.39
Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science (1992) 1.38
Strategies for immunotherapy of cancer. Adv Immunol (2000) 1.36
A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther (1997) 1.33
Lysine 271 in the transmembrane domain of the T-cell antigen receptor beta chain is necessary for its assembly with the CD3 complex but not for alpha/beta dimerization. J Biol Chem (1990) 1.29
Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol (1996) 1.26
Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother (2005) 1.25
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res (1999) 1.20
p53, a potential target for tumor-directed T cells. Immunol Lett (1994) 1.14
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res (1993) 1.11
Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res (2002) 1.09
p53: a potential target antigen for immunotherapy of cancer. Ann N Y Acad Sci (2000) 1.08
Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol (1998) 1.07
High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res (2000) 1.06
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res (1999) 1.03
Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther (2000) 1.02
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother (2004) 1.02
Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol (2000) 0.97
Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit (2003) 0.97
Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol (1995) 0.95
Focus on the p53 gene and cancer: advances in TP53 mutation research. Hum Mutat (2003) 0.95
P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res (2003) 0.92
Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer (1998) 0.91
TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol (2002) 0.91
The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship? Tumour Biol (2004) 0.87
The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J Surg Res (1997) 0.86
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res (2002) 0.86
Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res (2000) 0.85
p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol (2005) 0.82
p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. Mod Pathol (1994) 0.81
P53 immunostaining in melanocytic lesions. Eur J Cancer (1993) 0.80
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol (2005) 3.15
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol (2006) 3.15
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood (2004) 3.05
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother (2008) 2.57
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol (2006) 2.45
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27